Developing innovative solutions to debilitating diseases
AdAlta’s i-body® drug discovery platform goes where antibodies do not, to create new options for debilitating diseases
- Using i-bodies – with antibody features at a fraction of the size
- Developing next generation protein and cell therapies – focused on fibrosis and immuno-oncology
- Lead asset AD-214 – first in class product for treating fibrotic diseases
- i-CAR-T cell therapies (reprogramming immune cells) – providing new hope for patients with solid tumours
- i-PET imaging – helping cancer patients know early if their immunotherapy is working
More Info
AdAlta Media
- Proactive: The smart money in medicine: combatting fibrosis
- Proactive: AdAlta secures Chinese patent for AD-214
- The Market Herald: AdAlta $3.75m placement.
- Proactive: AdAlta’s inhaled fibrosis drug AD-214 passes first development milestone as firm begin raising cash
- AdAlta AGM 2021 Presentation Video
- Proactive: AdAlta well financed as it expands unique i-body technology
- IRD Invest: AdAlta Limited – Addressing new needs in patient care
- The Market Herald: AdAlta to pocket $4m low-interest loan from the Victorian government
- Edison Research: Moving into CAR-T
AdAlta Resources
